
Corona Remedies, a pharmaceutical company, saw its shares list at a 38% premium over the IPO price on the National Stock Exchange (NSE). The strong listing reflects robust investor demand and market enthusiasm for pharmaceutical stocks amid ongoing healthcare needs.









